Biohaven Therapeutics Ltd. — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications7liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BHV-7000The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.	Épilepsie	Phase 2/3	À vérifier	United States, Argentina, Austria, Belgium, Chile, Croatia, Czechia, France, …	À vérifier
BHV-8000 10mgA study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.	Parkinson	Phase 2/3	À vérifier	United States	À vérifier
BHV-8000 20 mgA study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.	Parkinson	Phase 2/3	À vérifier	United States	À vérifier
BHV-7000The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.	Épilepsie	Phase 2/3	À vérifier	United States, Australia, Denmark, Finland, Germany, Greece, Hungary, India, Italy, Mexico, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom	À vérifier
BHV-8000 10mgA study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.	Parkinson	Phase 2/3	À vérifier	United States	À vérifier
BHV-7000The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.	Épilepsie	Phase 2/3	À vérifier	United States, Argentina, Austria, Belgium, Chile, Croatia, Czechia, France, Hungary, Netherlands, Poland, Slovenia, South Africa, Switzerland	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
BHV-7000	Épilepsie	Phase 2/3	NCT06132893	RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	RECRUITING
BHV-8000 10mg	Parkinson	Phase 2/3	NCT06976268	A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease	RECRUITING
BHV-7000	Épilepsie	Phase 2/3	NCT06309966	RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	ACTIVE_NOT_RECRUITING

Publications

7

Molécule	Indication / population	Titre	Journal	Date
BHV-7000		Targeting Kv7 Potassium Channels for Epilepsy.	CNS drugs
BHV-7000		Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground?	Expert opinion on emerging drugs
BHV-8000 20 mg		Cost-effectiveness of providing pre-exposure and post-exposure prophylaxis for the prevention of HIV via online pharmacies in western Kenya: a modelling study.	The Lancet. Global health
BHV-8000 20 mg		Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.	Annals of the rheumatic diseases
BHV-8000 10mg		Molecular Mechanisms of Podophyllotoxin-Induced Subacute Kidney Injury: Oxidative Stress-Mediated Activation of the TRPM2-NOD-NF-κB Pathway.	Environmental toxicology and pharmacology
BHV-8000 10mg		Nephroprotective Effects of C Fullerenes in Chronic Glyphosate Intoxication.	Environmental toxicology and pharmacology
BHV-8000 10mg		Nutritional and hormone fortification of mulberry leaves enhances growth and improves immunity of silkworm larvae (Bombyx mori) to Beauveria bassiana.	Journal of invertebrate pathology